Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT00660036 Terminated - Clinical trials for Acute Myeloid Leukemia

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the combination of gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.

NCT ID: NCT00658411 Terminated - Clinical trials for Acute Myeloid Leukemia

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

Start date: August 2008
Phase: N/A
Study type: Interventional

The objective of this research study is to determine the safety and feasibility of chelation therapy with deferoxamine for patients with iron overload who are receiving a stem cell transplant. Patients who have iron overload prior to stem cell transplantation may have more toxicity from the transplantation procedure, and thus may benefit from an attempt at iron chelation pre- and peri-transplantation. In this study we are examining the use of deferoxamine starting 2 weeks to 3 months prior to transplantation and continuing through the preparative regimen.

NCT ID: NCT00655395 Terminated - Clinical trials for Acute Myeloid Leukemia (AML)

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Start date: March 2008
Phase: Phase 1/Phase 2
Study type: Interventional

- The purpose of the Phase I portion of this study is to evaluate the safety of this combination of medications and to determine the appropriate dose of VNP40101M to be used in combination with infusional cytarabine (araC) in elderly patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). - The purpose of the Phase II portion of the study is to evaluate the effectiveness (overall response rate) for patients treated with VNP40101M and infusional cytarabine induction therapy.

NCT ID: NCT00651716 Terminated - Breast Cancer Clinical Trials

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Start date: December 2006
Phase:
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease. PURPOSE: This clinical trial is studying T cells to see how well they help in predicting acute graft-versus-host disease in patients undergoing donor stem cell transplant.

NCT ID: NCT00648739 Terminated - Multiple Myeloma Clinical Trials

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Start date: June 19, 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of ALXN6000 (samalizumab) in treating relapsing or refractory B-cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM) and to study how samalizumab may help the immune system fight tumors that express CD200.

NCT ID: NCT00646165 Terminated - Clinical trials for B-cell Chronic Lymphocytic Leukemia

Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia

Start date: July 2008
Phase: Phase 1
Study type: Interventional

To determine the dose and duration of treatment for the best overall response with Forodesine in relapsed B-cell chronic lymphocytic leukemia

NCT ID: NCT00644878 Terminated - Clinical trials for Chronic Myelogenous Leukemia - Chronic Phase

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

MACS0254
Start date: October 2008
Phase: Phase 2
Study type: Interventional

This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib

NCT ID: NCT00643240 Terminated - Leukemia Clinical Trials

Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia

Start date: January 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. This may be effective treatment for leukemia. PURPOSE: This phase I trial is studying the best dose of yttrium Y 90-labeled monoclonal antibody BU-12 in treating patients with advanced relapsed or refractory acute lymphoblastic leukemia or chronic lymphocytic leukemia.

NCT ID: NCT00636155 Terminated - Clinical trials for Leukemia, Lymphocytic, Chronic

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see if the investigational drug EL625, when combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide), is effective in Persistent Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

NCT ID: NCT00631059 Terminated - Leukemia Clinical Trials

Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients

Start date: March 2008
Phase: N/A
Study type: Interventional

The objective of this protocol is to collect leukemia cell specimens from adults (18 years of age) diagnosed with acute leukemia at time of initial diagnosis and, if applicable, at time of first relapse. These specimens, in conjunction with a de-identified data set, will be utilized prospectively to determine potential chemotherapy resistance in this patient population. The specific aims of this study are as follows: To collect peripheral blood specimens from patients diagnosed with acute leukemia at time of initial diagnosis and, if applicable, at time of first relapse To evaluate the leukemia cells in the blood specimens for chemotherapy resistance utilizing the Hem(A)+ technology To develop a body of evidence from acute leukemia patients that demonstrates the applicability of the Hem(A)+ assay to determine the following: Predict responders and non-responders to common chemotherapeutic agents Track treatment results and comparison to prediction results from the assay Identify optimal chemotherapy doses for each patient Identify the most efficacious pharmaceutical agent combinations